Vaxart, Inc. 8K

Vaxart, Inc. announced positive Phase 2b sentinel safety data for its oral COVID-19 vaccine, expanded BARDA funding, Q2 2026 financial results showing a narrowed net loss and cash runway into Q2 2027, and scheduled an August 7, 2026 stockholder fireside chat.

On August 6, 2026, Vaxart, Inc. reported a business update and its second quarter 2026 financial results, highlighting topline safety data from the 400-person sentinel cohort of its Phase 2b COVID-19 oral pill vaccine trial showing no vaccine-related serious adverse events versus an approved mRNA comparator, confirmation of a BARDA contract modification raising total authorized study funding to $344.8 million, a cash balance of $64.0 million providing runway into the second quarter of 2027 alongside reduced R&D spending and a quarterly net loss of $13.5 million, and announced a stockholder fireside chat to be held on August 7, 2026.

Filing Facts

CIK

72444

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-026280

Alert Tier

6